



Regent Pacific Announces

Successful Acquisition of London AIM listed Plethora Solutions Holdings Plc

Transition into a Hong Kong Listed Healthcare Investment Vehicle

- ***Acquisition of London AIM listed Plethora Solutions Holdings plc became effective on 9 March 2016 with consideration shares issued in connection with the acquisition to commence trading on the Hong Kong Stock Exchange from today***
- ***Combined group will focus on pursuing late stage products in the healthcare and life sciences sectors and will work together to accelerate commercialization of Plethora's PSD502[®], a European approved treatment for premature ejaculation:***
 - ***EU launch scheduled for H2 2016***
 - ***Global market projected to be worth up to US\$3bn per annum***
 - ***Asia Pacific likely to become a key component to the eventual marketing and distribution of PSD502[®]***

(10 March 2016, Hong Kong) – Regent Pacific Group Limited (“Regent Pacific” or “the Group”; stock code: 00575) is pleased to announce today that it has successfully completed the acquisition of London AIM listed Plethora Solutions Holdings Plc (“Plethora” or the “Company”) through a recommended share exchange offer to the shareholders of the Company. Plethora became a wholly-owned subsidiary of the Group and dealings in consideration shares on the Hong Kong Stock Exchange will commence from today.

Plethora is a specialty pharmaceutical company based in the UK dedicated to the development and marketing of products for the treatment and management of urological disorders. Its principal product PSD502[®] is the first prescription treatment for premature ejaculation approved by the European Medical Agency (EMA), while preparations for a New Drug Application to the US Food and Drug Administration are advancing well. The agreed transaction enables the management team to accelerate the commercialization of the product through increased investment, with PSD502[®] scheduled to initially launch in EU in the latter half of 2016, and the key remaining markets of the US, Latin America and the Asia Pacific region to follow. The Asia Pacific region is likely to become an important component to the eventual marketing and distribution strategy for PSD502[®] over the longer term.

Jamie Gibson, CEO of Regent Pacific said, “We are delighted to have acquired Plethora and its high quality treatment for premature ejaculation, a condition affecting almost one in four men globally. This acquisition provides the Group with a strong platform for future growth and represents a significant



milestone in the refocusing of our strategy to the healthcare and life sciences sectors. Regent Pacific has become Hong Kong's first healthcare and life sciences investment vehicle to focus on sexual health, an area which has vast potential as the world's population ages and the regulatory landscape opens up. With the acquisition of Plethora now completed, Regent Pacific will be looking to build out a 'late stage' portfolio of healthcare and life sciences related investments, with PSD502[®] being the first, followed by our minority investment in Diabetic Boot Company."

"We are also delighted to welcome Michael Wyllie into the Group. His expertise will prove invaluable as we roll out PSD502[®] and identify 'late stage' products and commercialize them through 'out-licensing' to other strategic pharmaceutical partners, with the aim of delivering significant dividends to shareholders from royalty receipts."

Dr Michael Wyllie, Chief Scientific Officer of Plethora said, "Premature ejaculation is a serious condition affecting hundreds of millions of men across the globe and there is a dearth of medically approved treatments available to them. Our topical spray treatment PSD502[®] is an exceptional prescription treatment with the potential to transform lives and access a market potentially worth up to US\$3 billion per annum. We are excited to be joining forces with Jamie and his team at Regent Pacific. They have a strong track record of creating value in businesses and for shareholders, have excellent management acumen and share our passion for the healthcare industry. With appropriate funding from the enlarged Group now secured, we are well placed to achieve full commercialization of PSD502[®] across all key international markets, starting with the EU later this year through our commercial partner Recordati."

Following the transaction, Michael Wyllie, one of the former developers of Viagra and a founder of Plethora, joins Regent Pacific as its Chief Scientific Officer. He will join the Board as an executive Director at a later date. He will provide scientific overview and input to the development of PSD502[®] and work with Regent's senior management team to identify and evaluate exciting high growth and opportunistic 'late stage' investment opportunities in the life sciences sector. In particular, Regent Pacific believes that Greater China will become an increasingly important market for the commercialization of its 'late stage' products and in sourcing investment opportunities, as a result of favorable demographic trends, continuing urbanization, increasing disease burden, and growing affluence in the country, which is set to propel healthcare spending beyond US\$1 trillion by 2020¹.

The Group is one of a small number of investment vehicles focusing on healthcare and life sciences to trade on the Hong Kong Stock Exchange, providing local and China investors with a unique opportunity to participate in a sector with high growth prospects and a robust defensive nature amid a volatile global equity market.

- END -

¹ McKinsey Healthcare in China: Entering 'uncharted waters' (Nov 2012)



About Regent Pacific

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare and life sciences sectors. Its wholly-owned subsidiary, Plethora Solutions Holdings Plc, is a specialty pharmaceutical company whose core product PSD502[®] is the first EU approved topical prescription treatment for Premature Ejaculation, set to launch in EU in the latter half of 2016. The Group has a strong track record of investments and has returned US\$298 million to shareholders in the 17.5 years of financial reporting since its IPO.

For further information, please contact:

Finsbury

James Hill

t : 3166 9888

e : james.hill@finsbury.com

Karen Yu

t : 3166 9866

e : Karen.yu@finsbury.com